BLACKSBURG, Va.--(BUSINESS WIRE)--Techulon Inc., developer of low-toxicity DNA and RNA delivery technology, announced today that its platform was used successfully in a recent in vivo study focused on blocking downstream inflammatory pathways. Techulon’s polymers were used as delivery agents for an NF-?B oligodeoxynucleotide (ODN) decoy used to limit myocardial infarction during an ischemic-repurfusion event simulating a heart attack. This study compared the efficacy and toxicity of poly(glycoamidoamine)s (PGAA’s) against well known lipid and polyethyleneimine technologies for delivery of the decoy to H9c2 cells and cardiomyocytes in vitro, and to the in vivo murine heart.
